The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Cited by
Items 801–900 of 998
Racial distribution of molecularly classified brain tumors
Fang, C. S., Wang, W., Schroff, C., Movahed-Ezazi, M., Vasudevaraja, V., Serrano, J., Sulman, E. P., Golfinos, J. G., Orringer, D. A., Galbraith, K., et al. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae135 · Cited by 2
Prediction of the 3D cancer genome from whole-genome sequencing using InfoHiC
Lee, Y., Park, S., & Lee, H. (2024) · Molecular Systems Biology · doi:10.1038/s44320-024-00065-2 · Cited by 2
“After we performed WGS and RNA-seq analysis on data from these patients, the presence of driver mutations in coding regions were examined using cancer-related gene lists (Futreal et al, 2004; Northcott et al, 2017; Bailey et al, 2018) ( “ Methods and protocols ” ).”
Risk-Stratified Radiotherapy in Pediatric Cancer
Upadhyay, R., & Paulino, A. C. (2024) · Cancers · doi:10.3390/cancers16203530 · Cited by 5
Genomic landscape of medulloblastoma subtypes in an Asian cohort
Han, D., Jin, X., & Li, J. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-1350 · Cited by 2
Chen, T., Chen, H., Xia, M., Liao, Y., Li, H., Dong, X., Lin, Y., & Zhou, W. (2025) · npj Precision Oncology · doi:10.1038/s41698-024-00792-7 · Cited by 3
“…c-Myc, suggesting a new direction for targeted therapies in MYC - driven MB. Giventhe ongoing debate surrounding the classi fi cation criteria and tumor origins of the two subgroups 11,26 , we integrated them as a continuum in our analytical model and annotated with the reported clusters 10,11 .”
AZIN1 level is increased in medulloblastoma and correlates with c-Myc activity and tumor phenotype
Sesen, J., Martinez, T., Busatto, S., Poluben, L., Nassour, H., Stone, C. E., Ashok, K., Moses, M. A., Smith, E. R., & Ghalali, A. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03274-1 · Cited by 5
Germline Variants in Pediatric Cancer : Based on Oncogenic Pathways
Kim, J. W. (2025) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2025.0011 · Cited by 2
“3, encodes a subunit of the elongator complex that modifies tRNA 27 .”
Delaidelli, A., Burwag, F., Ben‐Neriah, S., Suk, Y., Shyp, T., Kosteniuk, S., Dunham, C. P., Cheng, S. S., Okonechnikov, K., Schrimpf, D., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf046 · Cited by 2
Self-citationAdult Medulloblastoma: Clinicomolecular Spectrum, An Institutional Experience
Adhvaryu, V., Gurav, M., Deshpande, G., Rumde, R., Shetty, O. A., Sahay, A., Sahu, A., Dasgupta, A., Chatterji, A., Gupta, T., et al. (2025) · International Journal of Surgical Pathology · doi:10.1177/10668969251332926 · Cited by 2
“22,23 However, this aberration is rarely observed in adults.”
Diversity of U1 Small Nuclear RNAs and Diagnostic Methods for Their Mutations
Nakashima, T., Miyauchi, T., Takeuchi, R., Sugihara, Y., Funakoshi, Y., Ohka, F., Maeda, S., Hirato, J., Yoshioka, T., Okita, H., et al. (2025) · Cancer Science · doi:10.1111/cas.70110 · Cited by 3
“This study included MAGIC, ICGC [8, 11], and original data from JCCG (Table S1).”
Thompson, D., Castle, J., Sill, M., Pfister, S. M., Bailey, S., Hicks, D., Clifford, S. C., & Schwalbe, E. C. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02049-1 · Cited by 3
“This hinders the detection of certain regions that are clinically relevant to MB, such as SNCAIP [10].”
Self-citationMiller, A. R., Shah, T., Strawser, C., Rivaldi, A., Wilson, S. A., Zhong, H., Lucyshyn, J. M., Garfinkle, E. A. R., McCoy, M., Cummins, S., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14711-x · Cited by 3
“For all panels, we also included a static list of 26 targets either present in the Twist Pan-Cancer cfDNA reference standard controls and/or genes or variants reported to be commonly altered in pediatric brain tumors (Supplementary Table S8) [25, 36, 37].”
The role of DNA methylation in directing treatment in medulloblastoma
Alsaedi, M. A. H., & Strathdee, G. R. (2025) · Epigenomics · doi:10.1080/17501911.2025.2554570 · Cited by 2
Alexandrova, E., Parisi, R., Smal, M. P., Rosa, D. D., Carleo, A., Orlando, E., Veneri, C., Melone, V., Salvati, A., Tarallo, R., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02730-3 · Cited by 2
“BRPF1 is also involved in adult Sonic hedgehog medulloblastoma (SHH-MB), which frequently harbors mutations in IDH1 and epigenetic modi fi ers such as BRPF1 and KANSL1 [106].”
Dias, M. V., Isom, B., Poole, K., Triplett, S., & Sadanandan, N. (2021) · Georgetown Scientific Research Journal · doi:10.48091/atjh8708 · Cited by 2
Molecular and clinical correlates of medulloblastoma subgroups: A narrative review
Coltin, H., & Ramaswamy, V. (2021) · Glioma · doi:10.4103/glioma.glioma_18_21 · Cited by 2
Self-citationNational supercomputing in Denmark
Andersen, L. K., Thage, B., Syed, A., Andersen, B., Løngreen, P., Nielsen, K. G., & Pedersen, S. (2018) · International Convention on Information and Communication Technology, Electronics and Microelectronics · doi:10.23919/mipro.2018.8400035 · Cited by 2
Are molecular subgroups of medulloblastomas really prognostic?
Frappaz, D., Faure‐Conter, C., Meyronet, D., Bonneville-Levard, A., Beuriat, P.-A., Sunyach, M. P., & Barritault, M. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000626 · Cited by 2
Prognostic value of molecular, genetic and clinical characteristics of SHH group medulloblastoma
Papusha, L. I., Druy, A. E., Yasko, L. A., Supik, Z. S., Земцова, Л. В., Эктова, А. П., Коновалов, Д. М., Voronin, K. A., Merishavyan, А. А., Бородина, И. Д., et al. (2018) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2018-17-3-43-49 · Cited by 2
Rare cases of medulloblastoma with hypermutation
Bagchi, A., Beddows, I., Cornelius, A. S., Robinson, G. W., & Jewell, S. D. (2021) · Cancer Reports · doi:10.1002/cnr2.1521 · Cited by 3
“(E) Mutation (missense and nonsense mutations) detected in list of commonly mutated genes in SHH-MB TABLE 1 Mutations in POLE hg 38 position CDS Change AA change COSMIC ID Type of variant Tumor ID 12:132673703 C - > A p. V411L COSV57677068 Missense T-10 12:132676157 A - > C p. D319E COSV57679046 Missense T-1 12:132665…”
BackgroundMethodSelf-citationSantosh, V., Rao, S. J., Dasgupta, A., & Gupta, T. (2021) · International Journal of Neurooncology · doi:10.4103/ijno.ijno_427_21 · Cited by 4
Amplifying natural antitumor immunity for personalized immunotherapy
Donovan, L., & Taylor, M. D. (2022) · Cell Research · doi:10.1038/s41422-022-00649-3 · Cited by 2
Self-citationCan abnormal chromatin folding cause high-penetrance cancer predisposition?
Schwartz, M. (2022) · Physiological Genomics · doi:10.1152/physiolgenomics.00052.2022 · Cited by 2
Bočkaj, I., Martini, T. E. I., Smit, M. J., Armandari, I., Bakker, B., Wardenaar, R., Boer, T. M.-D., Bakker, P. L., Spierings, D. C. J., Hoving, E. W., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179852 · Cited by 2
Expression pattern of MRPS18 family genes in medulloblastoma: a case report
Kovalevska, L. M., Щербіна, В. М., Kalman, S. S., Verbova, L. M., Розуменко, В. Д., Малышева, Т. А., & Kashuba, E. (2022) · Ukrainian Neurosurgical Journal · doi:10.25305/unj.265302 · Cited by 2
Introduction: Ongoing clinical challenges in the management of meningiomas and future directions
Wang, J. Z., Nassiri, F., Aldape, K., & Zadeh, G. M. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad030 · Cited by 2
Tam, O., Ho, R. S. L., Chan, S., Li, K. K. W., Lam, T.-L., Cheung, E. T.-Y., Cheung, O.-Y., Ho, W. W.-S., Cheng, K. K. F., Shing, M. M. K., et al. (2023) · Cancers · doi:10.3390/cancers15194880 · Cited by 2
“In addition to the four medulloblastoma groups described, SHH tumors have since then been divided into four subtypes and Group 3/4 in to eight subtypes [16].”
BackgroundWang, D., Ma, K., Deng, W., Li, J., Xiang, S., Zhang, Y., Fu, Y., Dai, H., & Huang, B. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s299381 · Cited by 4
“25,26 Briefly, plenty of candidate SNVs/ INDELs were identified in tumour samples with at least three supported reads and the required mapping quality and base quality score.”
Challenges and Recent Advances of Novel Chemical Inhibitors in Medulloblastoma Therapy
Maurya, A., Patel, U. K., Yadav, J. K., Singh, V. P., & Agarwal, A. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1952-0_13 · Cited by 2
Cormerais, Y., Pagnuzzi-Boncompagni, M., Schrötter, S., Giuliano, S., Tambutté, É., Endou, H., Wempe, M. F., Pagès, G., Pouysségur, J., & Picco, V. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/428722 · Cited by 2
“The most recent studies combining genetics, epigenetics and RNA expression data have refined and further delineated several sub-groups within these groups [3-6].”
BackgroundPagnuzzi‐Boncompagni, M., Picco, V., Vial, V., Planas-Bielsa, V., Vandenberghe, A., Grépin, R., Durivault, J., Montemagno, C., Martial, S., Doyen, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.18.301028 · Cited by 2
“Recent advances in the genetic characterization of the disease have led to the classification of MBs into subtypes: the wingless (Wnt), the sonic hedgehog (Shh), and the more similar though molecularly distinguishable groups 3 and 4 [2].”
BackgroundAn early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma
Shih, H. A. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab179 · Cited by 2
Mangum, R., & Parsons, D. W. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac048 · Cited by 2
Cell-state plasticity drives heterogeneity in Group 3/4 medulloblastomaPreprint
Joshi, P. K., da Silva, P. B. G., Okonechnikov, K., Stelzer, T., Sarropoulos, I., Sepp, M., Nolle, J., Pour-Jamnani, M. V., Rademacher, A., Yamada-Saito, T., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.09.579680 · Cited by 4
“Overlaying common genetic driver events 8,14 onto this landscape suggested a causal relationship between driver alterations and tumor phenotype.”
InfluentialSelf-citationModelling medulloblastoma pathogenesis and treatment in human cerebellar organoidsPreprint
Willott, T., Nicholson, J. G., Xiao, Y., Ogunbiyi, O. K., Draper, B., Mistry, T., Donovan, L., Zabet, N. R., Merve, A., Badodi, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.14.607977 · Cited by 2
Chromatin interaction maps identify oncogenic targets of enhancer duplications in cancer
Song, Y., Li, F., Wang, S., Wang, Y., Lai, C., Chen, L., Jiang, N., Li, J., Chen, X., Bailey, S. D., et al. (2024) · Genome Research · doi:10.1101/gr.278418.123 · Cited by 2
Consistently processed RNA sequencing data from 50 sources enriched for pediatric data
Beale, H. C., Learned, K., Kephart, E. T., Lyle, A. G., van den Bout, A., McCabe, M. M., Echandia-Monroe, K., Khare, M. J., Huang, E. Y., Jariwala, S., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-05376-z · Cited by 3
Modeling medulloblastoma pathogenesis and treatment in human cerebellar organoids
Willott, T., Nicholson, J. G., Zhang, X., Xiao, Y., Ogunbiyi, O. K., Draper, B., Mistry, T., Donovan, L., Merve, A., Zabet, N. R., et al. (2026) · Genes & Development · doi:10.1101/gad.353292.125 · Cited by 5
“Next, we set out to assess whether CbOs could provide a physiologically relevant 3D environment for sustaining the growth of human MB cells (CbO-MBs).”
InfluentialGangwani, K., Lu, C., Dhanda, S. K., Sioson, E., Zaldívar Peraza, A., Matt, G. Y., Paul, R., Wang, J., Reilly, C., Acić, A., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4976 · Cited by 1
“In particular, DNA methylation profiling coupled with machine learning algorithms has identified eight molecular subgroups within G3 and G4 (5, 8, 14, 15).”
InfluentialSelf-citationJones, V. M., Kanter, J. H., Russo, G. A., Simmons, N. E., Tafe, L. J., & Zanazzi, G. J. (2024) · International Journal of Surgical Pathology · doi:10.1177/10668969231201411 · Cited by 1
“20,21 Chen et al. showed that the p.R313delinsPRR insertion elicits ubiquitylation and degradation of the REST Corepressor (CoREST), thereby altering transcription to promote the survival of cancer stem cells.”
Chromatin Immunoprecipitation Assays on Medulloblastoma Cell Line DAOY
Dobson, T., & Swaminathan, J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1952-0_4 · Cited by 1
Liu, Y., Glessner, J., Qu, H., Chang, X., Qiu, H., Wang, T., Mentch, F. D., & Hakonarson, H. H. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13718 · Cited by 1
“Structural variants affecting SNCAIP disrupt the local chromatin environment, promoting abnormal gene induction, particularly PRDM6 in medulloblastoma [16].”
Self-citationDinikina, Y. V., Zheludkova, O., Maizenger, P. A., Nikitina, I. L., Bezyazychnaya, I. V., Радулеску, Г. Г., Leonova, I. A., Косенкова, Т. В., Образцова, Г. И., Bashnina, E. B., et al. (2024) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2024-23-3-91-101 · Cited by 1
Basic Science of Pediatric Brain Tumors
Taccone, M. S., Srikanthan, D., Rutka, J. T., & Ramaswamy, V. (2024) · Springer eBooks · doi:10.1007/978-3-031-62017-1_7 · Cited by 1
Self-citationMining the epigenetic landscape of medulloblastoma (Review)
Aneja, K. K. (2024) · International Journal of Epigenetics · doi:10.3892/ije.2024.23 · Cited by 2
T-type calcium channels regulate medulloblastoma and can be targeted for therapy
Dube, C., Lai, M., Zhang, Y., Saha, S., Yener, U., Hanif, F., Hudson, K., Gibert, M. K., Marcinkiewicz, P., Sun, Y., et al. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-04967-5 · Cited by 1
“Medulloblastoma is classified into four molecular subgroups: SHH, WNT, Group 3 and Group 4 [5–7].”
Raskin, S. I., de Blank, P. M. K., Billups, C. A., Li, Y., Olson, J. M., & Leary, S. E. S. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf054 · Cited by 1
Mutations that stick: Unexpected discovery of molecular glue mimicry
Whelan, R., José‐Duran, F., & Mayor‐Ruiz, C. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.03.017 · Cited by 2
Zhao, H.-G., Ren, S.-K., Zhou, W., Liu, Z., Wang, L., Tian, Y., & Zhao, F. Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-00052-z · Cited by 1
Computational and biological modeling of IGF1R inhibition for multifocal medulloblastoma
Almer, A., Rasmussen, S. V., Kats, D., Svalina, M. N., Cole, B., Khani, M., Chen, S. D., Cheshier, S. H., Martin, B. A., Berlow, N., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00925-4 · Cited by 1
“Giventhelackofclear subtype membership, the omics data were further mapped on the genomic and transcriptomic data onto Subtypes I – VIII 25 , which previous work identi fi ed as further subdivisions of Group 3 and Group 4 speci fi cally, as shown in Fig.”
Fischer, T. T., Maaß, K. K., Schoof, M., Puranachot, P., Sievers, P., Montigel, S. H., Fluhr, T. L., Damaty, A. E., Seitz, A., Harrabi, S., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf110 · Cited by 1
Self-citationGABAergic Influences on Medulloblastoma
Buffon, V. A., Ribas-Filho, J. M., Malafaia, O., Tassinari, I. D., Roesler, R., & Isolan, G. R. (2025) · Brain Sciences · doi:10.3390/brainsci15070746 · Cited by 2
Hruby, L., Schaal, K., Delaidelli, A., Picard, D. J., Dunham, C. P., Lewandowska, O., Reiff, T., Larcher, M., Pouponnot, C., Sorensen, P. H. B., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02601-x · Cited by 4
“In line with that, we uncovered in the P fi ster cohort [7] that EIF4EBP1 expression is most elevated in subtypes II, III and V, which are characterized by MYC ampli fi cation (20% of cases for subtype II and 10% of cases for subtypes III and V [7]) (Fig.”
InfluentialOld Tools in a New Era: The Continued Relevance of Chemotherapy in Pediatric Neuro-Oncology
Felton, K. E. A., Lafay‐Cousin, L., & Cheng, S. S. (2025) · Current Oncology · doi:10.3390/curroncol32070410 · Cited by 3
Challenges and opportunities for treatment of medulloblastoma
Mehta, M., Somasundaram, D. B., Munshi, A., & Ramesh, R. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.06.006 · Cited by 3
CD34 ‐Positive Acral Chondromyxoid Mesenchymal Neoplasm Harboring a Novel TCF4::ERG Fusion
Honaker, E. C., Warmke, L. M., Ameline, B., Baumhoer, D., Baranov, E., Halper‐Stromberg, E., & Dehner, C. A. (2025) · Genes Chromosomes and Cancer · doi:10.1002/gcc.70073 · Cited by 1
de Estíbariz, I. M., Illarregi, U., Sinnett, D., Gutiérrez-Camino, Á., López-López, E., Zaldumbide, L., Laura Zaldumbide, M. G.-A., Alaña, L., Callado, L. F., Bilbao‐Aldaiturriaga, N., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf194 · Cited by 1
Li, Y., Liu, H., Liu, Y., Li, J., Suzuki, H. H., Liu, Y., Jiang, T., & Qiu, X. (2025) · Chinese Neurosurgical Journal · doi:10.1186/s41016-025-00405-7 · Cited by 1
“The specialized MB-CNN_ TP53/MYC/Chr11 models predicted high-risk genetic Medulloblastoma, the most common pediatric malignant brain tumor, is divided into four molecular subgroups, each with distinct prognostic implications [12, 20, 21].”
Self-citationla Cerda-Vargas, M. F. D., Schittenhelm, J., Ebinger, M., Zipfel, J., Beschorner, R., Tabatabai, G., & Schuhmann, M. U. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf266 · Cited by 2
Self-citationUthamacumaran, A. (2025) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416526500481 · Cited by 2
The Mutational Epidemiology of Childhood Cancer
Spector, L. G., Clark, C. J., Lu, Z., Anderson, N., Marcotte, E. L., & de Smith, A. J. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf154 · Cited by 1
Sun, M., Wang, J., & Wan, S. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70211 · Cited by 3
“Group 3 and Group 4 do not exhibit subgroup-defining mutations [12] but still have distinct clinic-biological features where Group 3 patients have the most unfavorable prognosis due to a higher incidence of ‘high-risk’ features, such as LCA (large cell/anaplastic) histology and MYC amplification…”
Detection of structural DNA variants in medulloblastomas using optical genome mapping
Kubon, N., Balan, M., Koppstein, D., Praeger, S., Wolter, M., Ebert, P., Pauck, D., Felsberg, J., Beez, T., Picard, D., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02245-7 · Cited by 1
“…(SNVs) leading to loss-of-function or activating mutations of tumor suppressor genes or proto-oncogenes are well-documented in different MB groups [39], characterization of SVs is mostly limited to detection of copy number variants (CNVs) including numerical aberrations of whole chromosomes or…”
Rosenbaum, A., Wibom, C., Suger, A. H., Pensch, R., Roy, A., Brännström, T., Rentoft, M., Forsberg‐Nilsson, K., Lindblad‐Toh, K., Lindström, S., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag038 · Cited by 1
“58 Somatic mutations in CREBBP have been reported in medulloblastoma, 59 but are uncommon in glioma.”
Chesney, K. M., Whiteaker, J. R., Hood, B. L., Zhou, M., Zhang, H., Rivero-Hinojosa, S., Paulovich, A. G., Conrads, T. P., & Rood, B. R. (2026) · Cells · doi:10.3390/cells15050474 · Cited by 3
Liu, H., Su, Y., Zhang, J., Chen, X., Deng, K., Chen, L., Feng, J., Wu, X., Daniels, C., Li, Y., et al. (2026) · Med · doi:10.1016/j.medj.2026.101076 · Cited by 1
Self-citationProtein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models
Ho, W. S., Mondal, I., Liu, J., Sun, R., Huo, J., Gao, C., Das, O., Tieu, D., Sun, J., Lin, H., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci196753 · Cited by 2
“We therefore applied NetBID2, a network-based algorithm that infers regulatory protein activity from transcriptomic data using gene regulatory networks (24, 25), to publicly available MB RNA-Seq datasets (26).”
Kopp, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1811760 · Cited by 1
“Some aggressive tumors appear with few, if any, consistent drivers (4, 5).”
Is adult medulloblastoma merely the counterpart of pediatric medulloblastoma?
Ng, H., Wong, G. C.-H., Li, K. K.-W., & Poon, M. F. (2020) · Glioma · doi:10.4103/glioma.glioma_24_20 · Cited by 1
Proteogenomics for pediatric brain cancer
Simonian, M. (2021) · Biocell · doi:10.32604/biocell.2021.017369 · Cited by 1
Le médulloblastome : les dernières avancées majeures
Contenti, J., Bost, F., & Mazure, N. M. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.02.002 · Cited by 2
Liang, L., Borlase, S., Aiken, C., Felton, K. E. A., Hogg, A., van Landeghem, F. K. H., Klonisch, T. C., Eisenstat, D. D., & Werbowetski‐Ogilvie, T. E. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-23104-9_19 · Cited by 1
In-depth understanding of higher-order genome architecture in orphan cancer
Ding, T., Zhang, J., Xu, H., Zhang, X., Yang, F., Shi, Y., Bai, Y., Yang, J., Chen, C., & Zhang, H. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188948 · Cited by 2
Self-citationLuo, M., Chen, Y., Yin, X., & Li, J. N. (2024) · International Journal of Surgical Pathology · doi:10.1177/10668969241231971 · Cited by 1
Lacruz, C. R., & Leonardo, E. (2023) · Springer eBooks · doi:10.1007/978-3-031-51078-6_9 · Cited by 1
Obrecht, D., Schömig, L., Mynarek, M., Bison, B., Schwarz, R., Pietsch, T., Pfister, S. M., Sill, M., Sturm, D., Sahm, F., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae071 · Cited by 2
Self-citationLeading medulloblastoma to a differentiation end
Nör, C., & Ramaswamy, V. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.07.011 · Cited by 1
Self-citationEpigenetic reprogramming enables NF1A/B oncogenic role in SHH medulloblastoma
Badodi, S., & Marino, S. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.07.002 · Cited by 1
When do I ask for a DNA methylation array for primary brain tumor diagnosis?
Barresi, V., & Poliani, P. L. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001089 · Cited by 1
Krüger, C., Paplomatas, P., Kreuter, N., Hellwig, M., Eckhardt, A., Conze, C., Oliveira‐Ferrer, L., Tischendorf, J., Thaden, V., Schüller, U., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100950 · Cited by 1
MOADE: a multimodal autoencoder for dissociating bulk multi-omics data
Sun, J., Malik, A. A., Lin, T., Bratton, A., Pan, Y., Smith, K. S., Onar‐Thomas, A., Robinson, G. W., Zhang, W., Northcott, P. A., et al. (2025) · Genome biology · doi:10.1186/s13059-025-03805-1 · Cited by 1
Self-citationPathology and Classification of Tumors of the Central Nervous System
Reifenberger, G., Blümcke, I., Wesseling, P., Pietsch, T., & Paulus, W. (2019) · Springer eBooks · doi:10.1007/978-3-030-04152-6_1 · Cited by 1
Expected future developments in child neurology
Tein, I. (2019) · Journal of the International Child Neurology Association · doi:10.17724/jicna.2019.158 · Cited by 1
The advent of precision epigenetics for medulloblastoma
Li, C., & Meir, E. G. V. (2020) · Oncoscience · doi:10.18632/oncoscience.507 · Cited by 1
“MB can be subdivided into four clinically and molecularly distinct groups: wingless (WNT), sonic hedgehog (SHH), and groups 3 and 4 [2].”
BackgroundIn Vivo Medulloblastoma Modeling
Mirabal-Ortega, L., Larcher, M., Morabito, M., Foray, C., Duvillié, B., Eychène, A., & Pouponnot, C. (2020) · Neuromethods · doi:10.1007/978-1-0716-0856-2_2 · Cited by 1
Update in Pediatric Neuro-Oncology
Khatua, S., & Pillay Smiley, N. (2019) · MDPI eBooks · doi:10.3390/books978-3-03897-540-3 · Cited by 1
Li, H., Wang, Y., Yan, J., Ji, G., Tseng, H., & Chen, C.-C. (2022) · Sensors and Materials · doi:10.18494/sam3524 · Cited by 1
Prognostic value of microRNA-125a expression status in molecular groups of pediatric medulloblastoma
Hamam, S. M., Abdelzaher, E., Fadel, S. H., Nassra, R. A., & Sharafeldin, H. A. (2023) · Child s Nervous System · doi:10.1007/s00381-023-05899-z · Cited by 2
“However, these groups are heterogeneous, and they need more research to improve the molecular understanding and management of MB [8].”
BackgroundInfluentialFuster, J. L., Jiménez, I., Campillo, J. A., Blanquer, M., Cortés, M. B., Minguela, A., Llinares, M. E., Sánchez‐Salinas, A., Galera, A., Girón, O. F. Z., et al. (2023) · Annals of Case Reports · doi:10.29011/2574-7754.101184
IMPROVING PRECISION IN THERAPIES FOR HEMATOLOGICAL MALIGNANCIES
Majumder, M. M. (2018) · Helda - University of Helsinki Institutional Repository · Cited by 3
Live cell monitoring for factors affecting genome variationPreprint
Xia, Y., Zhu, K., Irianto, J., Andrechak, J. C., Dooling, L. J., Pfeifer, C. R., & Discher, D. E. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/508150 · Cited by 2
The Topology of Mutated Driver PathwaysPreprint
Dridi, R., Alghassi, H., Obeidat, M., & Tayur, S. R. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/860676 · Cited by 1
“Both algorithms are in widespread use in whole-genome analysis–for instance, in [16, 17, 4, 20].”
Sanders, A. D., Meiers, S., Ghareghani, M., Porubskỳ, D., Jeong, H., van Vliet, M. A. C. C., Rausch, T., Richter‐Pechańska, P., Kunz, J. B., Jenni, S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/849604 · Cited by 1
Self-citationPediatric cerebellar tumors: transcriptionally distinct but developmentally heterogeneous
Bhattacharya, D., Krummel, D. P., & Sengupta, S. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.01.31 · Cited by 1
“Medulloblastoma tumors show wellcharacterized intertumoral heterogeneity, as well as spatial (in metastases) and temporal heterogeneity at recurrence (4-7).”
BackgroundMethodShimada, I. S., Hwang, S., Somatilaka, B. N., Wang, X., Skowron, P., Kim, J., Kim, M., Shelton, J. M., Rajaram, V., Xuan, Z., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3155780 · Cited by 1
Self-citationYang, R., Wang, W., Dong, M., Roso, K., Greer, P. K., Bao, X., Pirozzi, C. J., Bigner, D. D., Yan, H., Ashley, D. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.07.447394 · Cited by 1
Molecular profile reveals immune-associated markers of medulloblastoma for different subtypesPreprint
Li, S., Kang, Z., Chen, J., Wang, C., Cai, Z., Pan, L., Chen, F., lishenglan, & liwenbin (2021) · Research Square · doi:10.21203/rs.3.rs-816357/v1 · Cited by 1
Childhood cancer mutagenesis caused by a domesticated DNA transposasePreprint
Keller, R. R., Yamada, M., Cameron, D., Suzuki, H., Sanghrajka, R. M., Vaynshteyn, J., Gerwin, J. N., Maura, F., Hooper, W. F., Shah, M. J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.05.498128 · Cited by 1
Self-citationPomella, S., Cassandri, M., Cossetti, C., Phelps, D. A., Perrone, C., Pezzella, M., Cardinale, A., Wachtel, M., Colletti, M., Walters, Z. S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2312251/v1 · Cited by 1
Voß, H., Godbole, S., Schlumbohm, S., Schumann, Y., Peng, B., Mynarek, M., Rutkowski, S., Dottermusch, M., Dorostkar, M. M., Koshunov, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.09.523234 · Cited by 1
Self-citation
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.